GERMANTOWN, Md.–(BUSINESS WIRE)–Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology
company focused on the development and commercialization of a long-term,
implantable continuous glucose monitoring (CGM) system for people with
diabetes, today announced that it plans to release its first quarter
2019 financial results after market close on Thursday, May 9, 2019.
Management will hold a conference call to review the company’s first
quarter 2019 performance starting at 4:30 p.m. (Eastern Time) on the
same day. The conference call will be concurrently webcast. The link to
the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com
by navigating to “Investor Relations,” and then “Events & Publications,”
and will be archived there for future reference. To listen to the
conference call, please dial 888-378-4398 (US/Canada) or 786-789-4775
(International), passcode 756769, approximately ten to five minutes
prior to start time.
Senseonics Holdings, Inc. is a medical technology company focused on the
design, development and commercialization of transformational glucose
monitoring products designed to help people with diabetes confidently
live their lives with ease. Senseonics’ CGM systems, Eversense® and
Eversense® XL, include a small sensor inserted completely under the skin
that communicates with a smart transmitter worn over the sensor. The
glucose data are automatically sent every 5 minutes to a mobile app on
the user’s smartphone.
Lynn Lewis or Philip Taylor